Volume 1.29 | Aug 6

Prostate Cell News 1.29, August 6, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


Inhibiting FASN Gene May Reduce Prostate Cancer Mortality in Overweight Men 
Study results indicated that the poor outcomes often experienced by overweight men with prostate cancer may be mediated by the fatty acid synthase (FASN) gene. [Press release from Medwire News discussing online prepublication in the Journal of Clinical Oncology]

Watch Procedure Now  
Use ALDEFLUOR® to Detect Prostate Precursor Cells
by STEMCELL Technologies


Five New Genetic Variations Linked With Prostate Cancer Uncovered in Study on Japanese Men
A genome-wide study on Japanese subjects has identified 5 new genetic variations linked to prostate cancer and revealed differences and similarities between Europeans and Asians in susceptibility to the disease. [Press release from RIKEN discussing online prepublication in Nature Genetics]

Use of Some Common Drugs May Lower PSA Levels
The use of nonsteroidal anti-inflammatory drugs, statins, or thiazide diuretics can significantly lower tested levels of prostate-specific antigen (PSA). [Press release from ModernMedicine discussing online prepublication in the Journal of Clinical Oncology]

Watch Procedure Now  
Optimized Enzymes and Protocols for
Prostate Tissue Dissociation

by STEMCELL Technologies

CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)


eIF4E Phosphorylation Promotes Tumorigenesis and is Associated with Prostate Cancer Progression
Here, researchers showed that knock-in mice expressing a nonphosphorylatable form of eIF4E are resistant to tumorigenesis in a prostate cancer model. [Proc Natl Acad Sci USA]

Expression of Receptors for Luteinizing Hormone-Releasing Hormone (LH-RH) in Prostate Cancers Following Therapy with LH-RH Agonists 
The findings support the concept of targeting cytotoxic LH-RH analogs to prostatic LH-RH receptors, using these receptors to gain entry into cancer cells to deliver a hybridized cytotoxic moiety for the treatment of prostate cancer. [Clin Cancer Res]

High Density Lipoprotein Induces Proliferation and Migration of Human Prostate Androgen Independent Cancer Cells by an ABCA1-dependent Mechanism
In this study, scientists investigated the effect of high density lipoprotein on prostate cancer cell proliferation, migration, intracellular cholesterol levels, and the role of cholesterol transporters, namely ABCA1, ABCG1 and SR-BI in these processes. [Mol Cancer Res]

Oxytocin Induces the Migration of Prostate Cancer Cells: Involvement of the Gi-Coupled Signaling Pathway
Investigators concluded that a Gi-dependent mechanism is involved in oxytocin receptor-mediated migration of prostate cancer cells, and indicates a role for oxytocin receptor in prostate cancer metastasis. [Mol Cancer Res]

Preferential Induction of G1 Arrest in Androgen-Responsive Human Prostate Cancer Cells by Androgen Receptor Signaling Antagonists DL3 and Antiandrogen Bicalutamide
The purpose of this study was to further characterize cell growth-inhibitory effects of a recently identified androgen receptor signaling inhibitor 6-amino-2-[2-(4-tert-butyl-pnenoxy)-ethylsulfanyl]-1H-pyrimidin-4-one and antiandrogen bicalutamide. [Cancer Lett]

Inhibition of ADAM9 Expression Induces Epithelial Phenotypic Alterations and Sensitizes Human Prostate Cancer Cells to Radiation and Chemotherapy
In this study, researchers determined the role of ADAM9 in the therapeutic resistance to radiation and chemotherapy. [Prostate]

Effect of Androgen Deprivation Therapy on the Expression of Prostate Cancer Biomarkers MSMB and MSMB-Binding Protein CRISP3
Using an Affymetrix cDNA microarray analysis, scientists investigated the expression of [beta]-microseminoprotein (MSMB), cysteine-rich secretory protein-3 (CRISP3), androgen receptor, KLK3 and Enhancer of Zeste Homologue-2 (EZH2) in tissue from prostate cancer patients receiving or not receiving androgen deprivation therapy before radical prostatectomy. [Prostate Cancer Prostatic Dis]

Curcumin Interrupts the Interaction Between the Androgen Receptor (AR) and Wnt/Beta-Catenin Signaling Pathway in LNCaP Prostate Cancer Cells
In this study, whether curcumin mediates the Wnt/[beta]-catenin signaling pathway with regard to AR/beta-catenin interactions was studied. [Prostate Cancer Prostatic Dis]


Genome-Wide Association Study Identifies Five New Susceptibility Loci for Prostate Cancer in the Japanese Population
Here, investigators carried out a genome-wide association study and replication study using 4,584 Japanese men with prostate cancer and 8,801 control subjects. [Nat Genet]

Fatty Acid Synthase Polymorphisms, Tumor Expression, Body Mass Index, Prostate Cancer Risk, and Survival
Researchers examined whether common germline single nucleotide polymorphisms in the fatty acid synthase gene affect prostate cancer (PCa) risk or PCa-specific mortality and whether these effects vary by body mass index. [J Clin Oncol]

Impact of Common Medications on Serum Total Prostate-Specific Antigen Levels: Analysis of the National Health and Nutrition Examination Survey
Scientists investigated the impact of individual and combinations of common medications on prostate-specific antigen in a large cross-sectional study of the United States population. [J Clin Oncol]


Canadian Researchers Testing Unique Vaccines for Prion Diseases and Common Cancers
Several Canadian researchers have come together to help control the relentless spread of a prion disease, chronic wasting disease in deer and elk, through vaccines. At the same time they aim to generate safe and effective therapies for common cancers. [PrioNet Canada Press Release]

British Companies to Receive Support to Develop New Regenerative Medicine Products and Technologies
The government-backed Technology Strategy Board is to invest over £5 million to support the research and development in the UK of new regenerative medicine products, tools and technologies. 16 research and development projects in the field of regenerative medicine therapeutics are to receive a total of £3.6 million of investment, while a further £1.6 million is to be invested in 12 feasibility studies in the area of regenerative medicine tools and technologies. [Technology Strategy Board Press Release, United Kingdom]

Oxford BioMedica Announces FDA Approval for TroVax® Phase II Study in Prostate Cancer
Oxford BioMedica announced that it has received approval from the U.S. Food and Drug Administration (FDA) and Recombinant DNA Advisory Committee to initiate a clinical Phase II study in the United States to assess the activity of TroVax® (MVA-5T4) in patients with progressive hormone refractory prostate cancer. [Oxford BioMedica Press Release]

OncoGenex Reports Second Quarter Financial Results
OncoGenex Pharmaceuticals, Inc. reported unaudited financial results for the three and six months ended June 30, 2010 and reviewed the Company’s highlights for the second quarter of 2010. [OncoGenex Pharmaceuticals, Inc. Press Release]

Invivo Wins Medical Design Excellence Award for Prostate Solutions
On June 9, 2010, Invivo was recognized with a 2010 Gold Medical Design Excellence Award for its DynaCAD for Prostate and DynaTRIM (Trans-Rectal Interventional MRI) clinical solutions. [Invivo Corporation Press Release]


Call for Cancer Test Funding
The Prostate Cancer Foundation of Australia wants whoever wins this month’s federal election to fund a major national campaign to encourage Australian men to have the PSA (prostate-specific antigen) test for the disease. [The Prostate Cancer Foundation of Australia, Australia]

MHRA Business Plan 2010 and Corporate Plan 2010-15 Published
The MHRA gained ministerial agreement for the Agency’s Business Plan 2010 and the Corporate Plan 2010-15. [Medicine and Healthcare Products Regulatory Agency, United Kingdom]

Regulation of Advanced Therapy Medicinal Products in the UK
The statutory instrument for implementing the UK’s requirements under the hospital exemption scheme (The Medicines for Human Use (Advanced Therapy Medicinal Products and Miscellaneous Amendments) Regulations 2010) was laid in Parliament on 26 July 2010. [Medicine and Healthcare Products Regulatory Agency, United Kingdom]

Risk Evaluation and Mitigation Strategy (REMS) Public Meeting
The Food and Drug Administration announced a 2-day public meeting to obtain input on issues and challenges associated with the development and implementation of risk evaluation and mitigation strategies for drugs. An archived webcast of the meeting is available. [Food and Drug Administration, United States]

NSF Funding Request Faring Well in Congress
While the 2011 budget requests of other U.S. research agencies are struggling to stay afloat in choppy fiscal seas, so far National Science Foundation’s (NSF) is sailing through Congress largely intact. [National Science Foundation, United States]

Senate Spending Panel Approves $1 Billion Boost for NIH
A Senate subcommittee matched President Barack Obama’s request for a $1 billion increase in 2011 for the National Institutes of Health (NIH). That raise would bring the agency’s total budget to $32 billion, or 3.5% above the 2010 level, according to a statement from the Senate appropriations labor, health, and human services subcommittee. [National Institutes of Health, United States]

National Cancer Institute; Notice of Closed Meetings [National Institutes of Health, United States]

Agency Information Collection Activities: Proposed Collection; Comment Request [Agency for Healthcare Research and Quality, United States]

EVENTS (Listed by Date)

11th National Prostate Cancer Symposium
August 11-13, 2010
Melbourne, Australia

CHI’s 5th Annual Immunotherapeutics and Vaccine Summit (ImVacS)
August 17-19, 2010
Cambridge, United States

2010 World Cancer Congress
August 18-21, 2010
Shenzhen, China

NEW Ninth International Congress on Targeted Therapies in Cancer
August 20-22, 2010
Washington, United States

Joint Annual Meeting of the International Continence Society (ICS) and International Urogynecological Association (IUGA)
August 23-27, 2010
Toronto, Canada

Select Biosciences Inaugural Cellular Therapy Summit
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences 2nd Annual World Biobanking Summit
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences 3rd Annual Stem Cells Europe Conference
August 24-25, 2010
Edinburgh, Scotland

NEW The Science of Global Prostate Cancer Disparities in Black Men
August 27-29, 2010
Jacksonville, United States

28th World Congress of Endourology and SWL
September 1-4, 2010
Chicago, United States

Prostate Cancer Research Institute Conference 2010
September 11-12, 2010
California, United States

International Society for Cellular Therapy (ISCT) – Europe 2nd Regional Meeting
September 11-14, 2010
Belgirate, Italy

Tissue Engineering and Regenerative Medicine International Society (TERMIS) – Asia Pacific 2010
September 15-17, 2010
Sydney, Australia

2010 Prostate Cancer Canada (PCCN) Conference
September 22-25, 2010
Toronto, Canada

35th European Society for Medical Oncology (ESMO) Congress
October 8–12, 2010
Milan, Italy

Frontiers in Tumour Progression
October 24-27, 2010
Madrid, Spain

Cancer Pharmacogenetics: Personalising Medicine
November 22-24, 2010
Madrid, Spain

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Prostate Cell News.
Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives  |  Events  |  Subscribe  |  Contact Us